IDEXX LABORATORIES INC /DE

IDXX

IDEXX LABORATORIES INC /DE

IDXX

Insider Sentiment (TTM):

Last Purchase:-Last Sale:2026-03-03Shares Purchased (TTM):0Shares Sold (TTM):109,438.89

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:68,438,626Shares Outstanding:79,648,000Institutional Ownership Pct.:85.93%

Earnings Market Reaction:

Filing Date:2026-05-05Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Companies in In Vitro & In Vivo Diagnostic Substances

LNTH NEOG NTLA QDEL MYGN ACHV

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	201	180	208	165	164	288	309	402	397	454	332	133
Accounts Receivable Net Current	604	552	567	561	527	474	511	534	507	457	453	462
Inventory Net	382	378	392	393	396	382	390	380	391	380	394	395
Other Assets Current	268	304	310	245	230	256	224	213	207	204	206	189
Assets Current	1,454	1,414	1,477	1,362	1,318	1,400	1,434	1,529	1,502	1,495	1,384	1,179
Assets Noncurrent
Property Plant And Equipment Net	740	747	739	740	718	713	718	708	709	702	687	683
Operating Lease Right Of Use Asset	121	123	128	130	116	116	121	120	120	115	118	114
Goodwill	412	414	414	414	407	405	412	408	409	366	362	364
Intangible Assets Net Excluding Goodwill	105	110	115	104	107	112	107	111	115	85	87	91
Other Assets Noncurrent	553	542	514	581	548	548	559	540	499	497	448	439
Assets Noncurrent	1,931	1,937	1,910	1,968	1,896	1,894	1,917	1,886	1,852	1,765	1,702	1,692
Assets	3,385	3,351	3,387	3,331	3,214	3,293	3,351	3,415	3,354	3,260	3,086	2,871
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	130	110	122	117	120	114	111	117	117	111	113	108
Accrued Liabilities Current	454	530	489	417	491	502	511	541	476	479	420	399
Lines Of Credit Current	530	398	455	579	320	250	250	250	250	250	250	264
Long Term Debt Current	150	75	150	75	171	168	99	170	75	75	150	75
Contract With Customer Liability Current	36	35	36	36	35	34	38	38	38	37	37	38
Liabilities Current	1,300	1,149	1,252	1,224	1,136	1,068	1,009	1,117	957	952	970	884
Liabilities Noncurrent
Deferred Income Tax Liabilities Net	45	32	4	2	8	11	6	10	9	7	11	6
Long Term Debt Noncurrent	300	375	375	450	450	450	525	525	621	623	619	697
Contract With Customer Liability Noncurrent	32	32	31	32	27	27	27	27	28	29	28	29
Operating Lease Liability Noncurrent	99	101	106	108	97	98	103	103	104	100	101	97
Other Liabilities Noncurrent	54	57	58	57	48	44	63	53	66	66	60	64
Liabilities Noncurrent	530	597	574	648	629	630	723	718	828	824	819	893
Liabilities	1,829	1,745	1,826	1,872	1,766	1,698	1,733	1,835	1,785	1,775	1,789	1,777
Stockholders Equity Inclu…
Common Stock Value	11	11	11	11	11	11	11	11	11	11	11	11
Additional Paid In Capital Common Stock	1,861	1,827	1,793	1,727	1,696	1,674	1,646	1,625	1,605	1,570	1,543	1,515
Common Stock Other Value Outstanding	6	6	6	6	6	6	6	6	6	6	6	6
Retained Earnings Accumulated Deficit	6,670	6,392	6,144	5,869	5,575	5,332	5,116	4,883	4,680	4,445	4,250	4,038
Accumulated Other Comprehensive Income Loss Net Of…	-65	-69	-73	-77	-90	-94	-76	-85	-80	-71	-75	-74
Treasury Stock Common Value	-6,927	-6,561	-6,319	-6,078	-5,749	-5,334	-5,085	-4,860	-4,652	-4,475	-4,437	-4,402
Stockholders Equity	1,556	1,605	1,561	1,459	1,448	1,595	1,618	1,580	1,569	1,485	1,297	1,094
Liabilities And Stockholders Equity	3,385	3,351	3,387	3,331	3,214	3,293	3,351	3,415	3,354	3,260	3,086	2,871
Allowance For Doubtful Accounts Receivable Current	-	11	-	-	-	13	-	-	-	10	-	-
Common Stock Par Or Stated Value Per Share	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Common Stock Shares Authorized	120	120	120	120	120	120	120	120	120	120	120	120
Common Stock Shares Issued	109	108	108	108	108	108	108	108	108	108	107	107
Shares Outstanding	79	80	80	80	81	82	82	82	83	83	83	83
Common Stock Other Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Treasury Stock Common Shares	29	29	28	28	27	26	26	25	25	24	24	24

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	0.10%	-2.04%	-3.31%	-	-	-	-	-	-	-	-	-
2025	6.40%	11.15%	9.17%	-5.23%	-7.41%	-6.14%	4.14%	-4.77%	-4.02%	-9.73%	-11.43%	-11.89%
2024	10.35%	5.92%	0.03%	2.55%	9.04%	-3.83%	2.54%	1.31%	3.03%	-8.28%	-13.66%	8.60%
2023	-	-	-	-7.44%	-18.15%	-19.78%	20.95%	40.14%	32.50%	-7.27%	-12.87%	-10.76%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 50+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 50+ calculated metrics

Start free trial

Performance and Valuation Metrics

Metrics	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Liquidity Ratios
Current Ratio	1.12	1.23	1.18	1.11	1.16	1.31	1.42	1.37	1.57	1.57	1.43	1.33
Quick Ratio	0.82	0.90	0.87	0.79	0.81	0.95	1.03	1.03	1.16	1.17	1.02	0.89
Working Capital	154.22M	265.01M	225.24M	138.48M	181.40M	331.98M	424.52M	411.91M	545.07M	543.71M	414.04M	295.17M
Leverage & Debt
Debt to Equity	1.18	1.09	1.17	1.28	1.22	1.06	1.07	1.16	1.14	1.20	1.38	1.62
Interest Coverage TTM	36.12	35.01	35.17	36.72	37.01	36.16	33.72	31.94	30.68	26.39	23.51	21.73
Debt Ratio	0.54	0.52	0.54	0.56	0.55	0.52	0.52	0.54	0.53	0.54	0.58	0.62
Efficiency & Turnover
Asset Turnover TTM	1.35	1.30	1.24	1.20	1.20	1.19	1.19	1.20	1.21	1.22	1.25	1.28
Days Sales Outstanding TTM	46.42	43.51	47.21	49.46	48.03	43.59	45.76	48.00	46.70	42.77	42.77	45.43
Receivables Turnover TTM	7.86	8.39	7.73	7.38	7.60	8.37	7.98	7.60	7.82	8.53	8.53	8.03
Per Share Metrics
Diluted EPS TTM	13.66	13.08	12.74	12.17	10.92	10.67	10.43	10.14	10.32	10.06	9.80	9.42
Free Cash Flow Per Share TTM	13.60	13.14	12.03	9.75	10.42	9.80	9.63	10.15	9.59	9.30	8.18	7.13
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	62.05%	61.80%	61.72%	61.54%	61.28%	61.04%	60.72%	60.41%	60.14%	59.82%	59.89%	59.97%
Operating Profit Margin TTM	31.63%	31.60%	31.34%	31.09%	29.14%	28.95%	28.92%	28.62%	29.95%	29.97%	30.06%	29.82%
Net Profit Margin TTM	24.63%	24.62%	24.65%	24.41%	22.76%	22.78%	22.53%	22.34%	23.26%	23.08%	22.93%	22.52%
Growth Metrics
Net Revenue Growth (1Y)	13.08%	10.42%	8.39%	6.68%	5.56%	6.46%	7.16%	7.70%	8.57%	8.72%	7.43%	6.21%
Net Income Growth (1Y)	22.38%	19.33%	18.61%	16.56%	3.28%	5.07%	5.29%	6.85%	23.94%	24.44%	22.85%	19.21%
EPS Growth (1Y)	24.94%	22.35%	21.88%	19.77%	5.53%	5.83%	6.30%	7.44%	23.79%	25.27%	23.08%	20.41%
Valuation Metrics
P/E TTM	40.86	51.36	49.81	43.76	38.16	38.40	48.00	47.61	51.77	54.56	44.17	52.72
P/B TTM	28.76	33.89	32.78	29.56	23.58	21.37	25.70	25.48	28.60	31.06	28.01	38.15
P/S TTM	10.07	12.64	12.28	10.68	8.69	8.75	10.81	10.64	12.05	12.59	10.13	11.87
Market Cap	44.75B	54.41B	51.17B	43.13B	34.15B	34.10B	41.58B	40.26B	44.87B	46.11B	36.34B	41.73B
Enterprise Value	45.53B	55.08B	51.94B	44.07B	34.93B	34.67B	42.15B	40.80B	45.41B	46.60B	37.02B	42.63B
Calculated Values
Free Cash Flow TTM	1.08B	1.06B	963.57M	784.34M	847.70M	808.08M	792.60M	838.95M	796.79M	772.88M	679.78M	592.76M
Net Debt	779.32M	667.77M	771.66M	939.21M	776.26M	579.31M	565.26M	543.27M	548.34M	493.95M	687.11M	903.00M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-03-03Sale

Owner: Hunt, Nimrata

Title: Executive Vice President

Shares: 1,758

Price/Share: $634.57

Value: $1,115,574.06

Shares Owned: 18,141

Relationship: Officer

Ownership: Direct

2026-02-26Sale

Owner: Mazelsky, Jonathan Jay

Title: President and CEO

Shares: 23,326

Price/Share: $656.81

Value: $15,320,750.06

Shares Owned: 83,606

Relationship: Director,Officer

Ownership: Direct

2026-02-26Sale

Owner: Hunt, Nimrata

Title: Executive Vice President

Shares: 2,693

Price/Share: $661.54

Value: $1,781,527.22

Shares Owned: 19,899

Relationship: Officer

Ownership: Direct

2026-02-17Sale

Owner: Vandebroek, Sophie V.

Title: -

Shares: 1,464

Price/Share: $628.60

Value: $920,270.40

Shares Owned: 648

Relationship: Director

Ownership: Direct

2026-02-17Sale

Owner: Erickson, Michael G

Title: Executive Vice President

Shares: 5,371

Price/Share: $627.07

Value: $3,367,992.97

Shares Owned: 12,693

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-03-03	Hunt, Nimrata	Officer	Executive Vice President	Direct	Sale	1,758	634.57	$1,115,574.06	18,141	4
2026-02-26	Mazelsky, Jonathan Jay	Director,Officer	President and CEO	Direct	Sale	23,326	656.81	$15,320,750.06	83,606	4
2026-02-26	Hunt, Nimrata	Officer	Executive Vice President	Direct	Sale	2,693	661.54	$1,781,527.22	19,899	4
2026-02-17	Vandebroek, Sophie V.	Director	-	Direct	Sale	1,464	628.60	$920,270.40	648	4
2026-02-17	Erickson, Michael G	Officer	Executive Vice President	Direct	Sale	5,371	627.07	$3,367,992.97	12,693	4
2026-02-10	Fennell, George	Officer	Executive Vice President	Direct	Sale	11,345	646.76	$7,337,492.20	9,823	4
2025-11-07	Hunt, Nimrata	Officer	Executive Vice President	Direct	Sale	9,425	704.08	$6,635,954.00	21,149	4
2025-08-22	Szostak, M Anne	Director	-	Direct	Sale	2,187	647.33	$1,415,710.71	262	4
2025-08-12	Erickson, Michael G	Officer	Executive Vice President	Direct	Sale	406	649.92	$263,796.03	11,287	4
2025-08-11	Hunt, Nimrata	Officer	Executive Vice President	Direct	Sale	1,200	656.53	$787,836.00	16,807	4
2025-08-08	Underberg, Sharon E.	Officer	EVP, GC & Corporate Secretary	Direct	Sale	5,450	651.60	$3,551,220.00	6,156	4
2025-08-06	Hunt, Nimrata	Officer	Executive Vice President	Direct	Sale	7,143	630.49	$4,503,590.07	18,007	4
2025-08-06	Mazelsky, Jonathan Jay	Director,Officer	President and CEO	Direct	Sale	29,260	632.72	$18,513,387.20	83,311	4
2025-08-06	Lane, Michael	Officer	Executive Vice President	Direct	Sale	8,411	628.15	$5,283,369.65	7,132	4
2025-05-21	Szostak, M Anne	Director	-	Direct	Sale	1,046	513.74	$537,372.04	262	4
2025-05-13	Junius, Daniel M	Director	-	Direct	Sale	2,683	506.41	$1,358,698.03	3,304	4
2025-05-09	Vandebroek, Sophie V.	Director	-	Direct	Sale	1,279	491.34	$628,423.86	1,167	4
2025-02-10	Fennell, George	Officer	Executive Vice President	Direct	Sale	9,986	462.53	$4,618,824.58	8,176	4
2025-02-07	Szostak, M Anne	Director	-	Indirect	Sale	3,000	465.95	$1,397,850.00	3,061	4
2024-11-27	Vandebroek, Sophie V.	Director	-	Direct	Sale	344	420.44	$144,631.36	905	4
2024-09-06	Szostak, M Anne	Director	-	Indirect	Sale	500	469.37	$234,685.00	0	4
2024-05-17	Claflin, Bruce L.	Director	-	Direct	Sale	200	540.80	$108,160.00	161	4
2024-03-06	Polewaczyk, James F	Officer	Executive Vice President	Direct	Sale	8,104	558.72	$4,527,866.88	10,711	4
2024-03-05	Vandebroek, Sophie V.	Director	-	Direct	Sale	1,404	562.98	$790,423.92	1,216	4
2024-02-08	Fennell, George	Officer	SVP, Chief Revenue Officer	Direct	Sale	8,198	573.94	$4,705,160.12	6,712	4
2024-02-07	Mazelsky, Jonathan Jay	Director,Officer	President and CEO	Direct	Sale	12,000	573.53	$6,882,360.00	79,247	4
2024-02-07	Mckeon, Brian P	Officer	EVP, CFO and Treasurer	Direct	Sale	23,326	568.56	$13,262,230.56	29,718	4
2023-12-07	Polewaczyk, James F	Officer	Executive Vice President	Direct	Sale	11,636	521.76	$6,071,199.36	10,050	4
2023-12-04	Mazelsky, Jonathan Jay	Director,Officer	President and CEO	Direct	Sale	7,128	513.23	$3,658,303.44	79,233	4
2023-08-31	Mazelsky, Jonathan Jay	Director,Officer	President and CEO	Direct	Sale	13,424	512.01	$6,873,222.24	72,925	4
2023-08-29	Polewaczyk, James F	Officer	Executive Vice President	Direct	Sale	22,909	510.23	$11,688,859.07	10,038	4
2023-08-15	Ayers, Jonathan W	Director	-	Direct	Sale	492	0.00	$0.00	135,547	4
2023-08-03	Lane, Michael	Officer	Executive Vice President	Direct	Sale	16,027	510.00	$8,173,770.00	4,034	4
2023-05-19	Ayers, Jonathan W	Director	-	Direct	Sale	10,000	492.43	$4,924,300.00	137,039	4
2023-05-05	Lane, Michael	Officer	Executive Vice President	Direct	Sale	1,000	484.00	$484,000.00	4,022	4
2023-05-05	Szostak, M Anne	Director	-	Indirect	Sale	2,000	474.99	$949,980.00	4,700	4
2023-05-04	Vandebroek, Sophie V.	Director	-	Direct	Sale	2,187	469.02	$1,025,746.74	872	4
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

85.93%

Inst. Shares: 68,438,626

Shares Outstanding: 79,648,000

2025-12-31

86.35%

Inst. Shares: 69,452,488

Shares Outstanding: 80,427,000

2025-09-30

87.12%

Inst. Shares: 69,776,761

Shares Outstanding: 80,096,000

2025-06-30

88.86%

Inst. Shares: 71,452,797

Shares Outstanding: 80,413,000

2025-03-31

85.07%

Inst. Shares: 69,180,016

Shares Outstanding: 81,319,000

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	68,438,626	79,648,000	85.93%
2025-12-31	69,452,488	80,427,000	86.35%
2025-09-30	69,776,761	80,096,000	87.12%
2025-06-30	71,452,797	80,413,000	88.86%
2025-03-31	69,180,016	81,319,000	85.07%
2024-12-31	68,606,846	82,467,000	83.19%
2024-09-30	68,458,923	82,304,000	83.18%
2024-06-30	71,639,345	82,630,000	86.70%
2024-03-31	68,696,088	83,096,000	82.67%
2023-12-31	69,843,482	83,066,000	84.08%
2023-09-30	69,983,658	83,097,000	84.22%
2023-06-30	69,263,758	83,086,000	83.36%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

IDEXX LABORATORIES INC /DE (IDXX) — SEC Financial Statements & Analysis

IDEXX LABORATORIES INC /DE (IDXX) is a in vitro & in vivo diagnostic substances company, incorporated in DE. IDEXX LABORATORIES INC /DE trades on IDXX: Nasdaq as: IDXX. Based on its latest SEC filing (Form 10-Q, period ending 2026-03-31), IDEXX LABORATORIES INC /DE reported a 13.08% year-over-year revenue growth, a Gross Profit Margin of 62.05% (TTM), a Debt-to-Equity ratio of 1.18x, a Price-to-Sales (P/S) ratio of 10.07x (TTM), a Price-to-Book (P/B) ratio of 28.76 (TTM), at a market cap of $44.75B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 13.08%
Gross Profit Margin TTM: 62.05%
Debt To Equity: 1.18x
P/S TTM: 10.07x
P/B TTM: 28.76
Market Cap: $44.75B

Data as of 2026-03-31 · Source: SEC EDGAR

Frequently Asked Questions

What industry is IDEXX LABORATORIES INC /DE in?

IDEXX LABORATORIES INC /DE (IDXX) operates in the In Vitro & In Vivo Diagnostic Substances industry.

What is IDXX's market cap?

IDEXX LABORATORIES INC /DE (IDXX) has a market capitalization of $44.75B as of 2026-03-31.

What is IDXX's P/E ratio?

IDEXX LABORATORIES INC /DE (IDXX)'s trailing twelve month P/E ratio is 40.86x as of 2026-03-31.

What exchange does IDXX trade on?

IDEXX LABORATORIES INC /DE (IDXX) trades on the IDXX: Nasdaq.

Where is IDEXX LABORATORIES INC /DE incorporated?

IDEXX LABORATORIES INC /DE is incorporated in DE.

IDEXX LABORATORIES INC /DE (IDXX) — SEC Financial Statements & Analysis

Frequently Asked Questions

Research Faster.Invest Smarter.

Research Faster.
Invest Smarter.